Presentation is loading. Please wait.

Presentation is loading. Please wait.

5 MID Study 5 Year Mortality in Patients with Left Ventricular Diastolic Dysfunction and Preserved Ejection Fraction Catholic Health System, Buffalo, NY.

Published byChad Blake Modified over 9 years ago

Similar presentations

Presentation on theme: "5 MID Study 5 Year Mortality in Patients with Left Ventricular Diastolic Dysfunction and Preserved Ejection Fraction Catholic Health System, Buffalo, NY."— Presentation transcript:

1 5 MID Study 5 Year Mortality in Patients with Left Ventricular Diastolic Dysfunction and Preserved Ejection Fraction Catholic Health System, Buffalo, NY Salim H Memon M.B.B.S. Yuji Saito M.D., Ph.D., F.A.C.C.

2 Background Epidemiological Importance Olmsted County, Minnesota 2042 randomly selected residents (mean age 63) 5.6% had moderate or severe diastolic dysfunction with normal EF Cleveland Clinic study 36,261 adults (mean age 58) with LVEF ≥55% 65.2 % had diastolic dysfunction 5 MID Study

3 Background 5 MID Study Clinical Importance Asymptomatic Risk factor for DHF / HFpEF Heart failure Prevalence of more than 5 million 50% have DHF / HFpEF

4 Background Prognostic Importance Limited Studies available Increased Mortality with DD (3 significant studies) No increased Mortality with Mild/Grade 1 DD No mortality reducing drugs up to date 5 MID Study

5 Background Types of LV Dysfunction Systolic - Impaired cardiac contractility Diastolic - Abnormal cardiac relaxation, stiffness or filling Distinct disorders Not a continuous spectrum of disorders Can co-exist 5 MID Study

6 Background Terminology Diastolic Dysfunction Diastolic Heart Failure Heart Failure with Preserved Ejection Fraction (HFpEF) Characteristics: Normal LVEF Normal LV end-diastolic volume Abnormal diastolic function 5 MID Study

7 Normal Diastolic Function 5 MID Study Video from:

8 Abnormal Diastolic Function 5 MID Study Video from:

9 Diagnosis and Grading Requires Comprehensive assessment using Echocardiography Transmitral Doppler inflow velocity patterns Pulmonary venous Doppler flow patterns Tissue Doppler velocities Color M-mode flow propagation velocity 5 MID Study

10 Trans Mitral Doppler Inflow pattern 5 MID Study

11 Trans Mitral Doppler Inflow pattern 5 MID Study

12 Tissue Doppler (Septal) 5 MID Study e΄e΄ a΄a΄

13 Measuring IVRT from CW Doppler 5 MID Study

14 Grading Diastolic Dysfunction 5 MID Study

15 Study Design Study Flow Diagram Outcome Measures Methods Statistical Analyses used Results Conclusions Strengths and Limitations Future Considerations References Acknowledgements

16 Study Design Case Control Retrospective Analysis Comparison of patients with normal and abnormal diastolic function in terms of all cause mortality over 60 months from the date of 2- Dimensional Echocardiogram Institutional Review Board Approval Sisters of Charity Hospital 5 MID Study

17 Study Design Inclusion Criteria: Age ≥ 18 2-D Echocardiogram between Dec’07 – Dec’08 Preserved Ejection Fraction (≥50%) 5 MID Study

18 Study Design Exclusion Criteria: LV Ejection Fraction < 50% Atrial Fibrillation Unable to assess Diastolic function Unavailable Mortality Data Severe Mitral Valve Disease History of Mitral Valve Surgery Two 2D-Echocardiograms (2 nd Echo excluded) 5 MID Study

19 3018 Patients who has 2-Dimensional Echocardiograms from Dec’07 to Dec’08 were assessed for eligibility for the study Study Flow Diagram 5 MID Study 2107 Patients were excluded LV Ejection Fraction < 50% Atrial Fibrillation Unable to assess Diastolic function Unavailable Mortality Data Severe Mitral Valve Disease History of Mitral Valve Surgery 911 Patients included 250 Had normal diastolic function 661 Had diastolic dysfunction (abnormal diastolic dysfunction) Followed for 60 months for all cause mortality

20 Grading of Diastolic Dysfunction 5 MID Study

21 Outcome Measure All Cause Mortality 5 MID Study

22 Statistical Analyses IBM Statistical Package for Social Sciences (SPSS) software V.20 Continuous data expressed as Mean with 1 SD Categorical – Number (%) Analyze Group Differences: Continuous Variables: ANOVA Categorical Variables: χ ² tests Kaplin – Meier Curves – Unadjusted Survival Cox Regression Survival Analyses for adjusted survival 5 MID Study

23 Baseline Demographic and Clinical Characteristics 5 MID Study Characteristic No DD (N = 250) Grade 1 DD (N = 340) Grade 2 DD (N = 308) Grade 3 DD (N = 13) Total (N = 911) p-value Age – yr62.6 ± 15.473.7 ± 11.169.7 ± 13.175.7 ± 15.4<0.001 Male – No. (%)76 (30.4%)111 (32.6%)116 (37.7%)2 (15.4%)321 (33.5%)0.139 CAD – No. (%)48 (19.2%)83 (26.1%)78 (27.4%)3 (25.0%)212 (24.5%)0.138 HTN – No. (%)179 (71.6%)249 (78.3%)228 (80.0%)11 (91.7%)667 (77.1%)0.062 Hypercholestrolemia – No. (%) 115 (46.0%)190 (59.7%)154 (54.0%)6 (50.0%)465 (53.8%)0.013 Diabetes Mellitus -NIDDM – No. (%) -IDDM – No. (%) 43 (17.2%) 27 (10.8%) 48 (15.1%) 41 (12.9%) 52 (18.2%) 38 (13.3%) 3 (25.0%) 146 (16.9%) 109 (12.6%) 0.641 0.462 Total no. of Coronary Risk Factors 1.65 ± 1.161.92 ± 1.081.93 ± 1.162.17 ± 1.110.012 Race -Caucasian -African American -Other 163 (65.2%) 77 (30.8%) 10 (4%) 305 (89.7%) 24 (7.1%) 11 (3.2%) 258 (83.8%) 35 (11.4%) 15 (4.9%) 11 (84.6%) 1 (7.7%) 737 (80.9%) 137 (15.0%) 37 (4.0%) <0.001

24 Baseline Demographic and Clinical Characteristics 5 MID Study Characteristic No DD (N = 250) Grade 1 DD (N = 340) Grade 2 DD (N = 308) Grade 3 DD (N = 13) Total (N = 911) p-value Age – yr62.6 ± 15.473.7 ± 11.169.7 ± 13.175.7 ± 15.4<0.001 Male – No. (%)76 (30.4%)111 (32.6%)116 (37.7%)2 (15.4%)321 (33.5%)0.139 CAD – No. (%)48 (19.2%)83 (26.1%)78 (27.4%)3 (25.0%)212 (24.5%)0.138 HTN – No. (%)179 (71.6%)249 (78.3%)228 (80.0%)11 (91.7%)667 (77.1%)0.062 Hypercholestrolemia – No. (%) 115 (46.0%)190 (59.7%)154 (54.0%)6 (50.0%)465 (53.8%)0.013 Diabetes Mellitus -NIDDM – No. (%) -IDDM – No. (%) 43 (17.2%) 27 (10.8%) 48 (15.1%) 41 (12.9%) 52 (18.2%) 38 (13.3%) 3 (25.0%) 146 (16.9%) 109 (12.6%) 0.641 0.462 Total no. of Coronary Risk Factors 1.65 ± 1.161.92 ± 1.081.93 ± 1.162.17 ± 1.110.012 Race -Caucasian -African American -Other 163 (65.2%) 77 (30.8%) 10 (4%) 305 (89.7%) 24 (7.1%) 11 (3.2%) 258 (83.8%) 35 (11.4%) 15 (4.9%) 11 (84.6%) 1 (7.7%) 737 (80.9%) 137 (15.0%) 37 (4.0%) <0.001

25 Echocardiograhic Characteristics Degree of Diastolic Dysfunction → Grade 1Grade 2Grade 3p Value Echocardiograhic Characteristics ↓ E-wave velocity (cm/s)68 ± 1687 ± 26114 ± 25<0.001 A-wave velocity (cm/s)101 ± 2397 ± 2945 ± 14<0.001 E/A Velocity Ratio0.68 ± 0.180.92 ± 0.192.6 ± 0.59<0.001 Medial e' wave velocity (cm/s)9.8 ± 3.89.6 ± 3.98.2 ± 2.50.405 E/e' (medial) Velocity Ratio8.12 ± 4.5410.78 ± 5.9615.53 ± 5.34<0.001 IVRT (ms)99 ± 2585 ± 2261 ± 19<0.001 Deceleration Time (ms)293 ± 75247 ± 63178 ± 39<0.001 Left Atrial Size (cm)3.7 ± 0.84.1 ± 0.64.7 ± 0.7<0.001 Inter Ventricular Septum Size (cm)1.15 ± 0.361.12 ± 0.241.22 ± 0.350.026 Posterior Wall Size (cm)1.11 ± 0.251.09 ± 0.221.22 ± 0.35<0.001 LV Diameter - End Diastolic (cm)4.4 ± 0.74.6 ± 0.75.0 ± 0.7<0.001 LV Ejection Fraction (%)61 ± 6 62 ± 60.027 RVSP (mm Hg)35 ± 1040 ± 1347 ± 13<0.001 5 MID Study

26 Outcome: Normal Function vs DD 5 MID Study

27 Outcome: Normal Function vs DD 5 MID Study Vital Status → AliveDeceasedTotal Diastolic Dysfunction ↓ Present – No. (%)445 (67.3)216 (32.7)661 (100) Absent – No. (%)181 (72.4)69 (27.6)250 (100) Total – No. (%)626 (68.7)285 (31.3)911 (100)

28 Outcome: Normal Function vs DD 5 MID Study Vital Status → AliveDeceasedTotal Diastolic Dysfunction ↓ Present – No. (%)445 (67.3)216 (32.7)661 (100) Absent – No. (%)181 (72.4)69 (27.6)250 (100) Total – No. (%)626 (68.7)285 (31.3)911 (100) Diastolic Dysfunction as Risk for all cause mortality: Hazard Ratio = 1.325 (1.005 – 1.748) p-value = 0.046

29 Outcome: Normal Function vs different grades of DD 5 MID Study

30 Outcome: Normal Function vs different grades of DD Vital Status → AliveDeceasedTotal Grade of DD ↓ None – No. (%)181 (72.4)69 (27.6)250 (100) Grade 1 – No. (%)235 (69.1)105 (30.9)340 (100) Grade 2 – No. (%)204 (66.2)104 (33.8)308 (100) Grade 3 – No. (%)6 (46.2)7 (53.8)13 (100) Total – No. (%)626 (68.7)285 (31.3)911 (100)

31 Outcome: Normal Function vs different grades of DD Vital Status → AliveDeceasedTotal Grade of DD ↓ None – No. (%)181 (72.4)69 (27.6)250 (100) Grade 1 – No. (%)235 (69.1)105 (30.9)340 (100) Grade 2 – No. (%)204 (66.2)104 (33.8)308 (100) Grade 3 – No. (%)6 (46.2)7 (53.8)13 (100) Total – No. (%)626 (68.7)285 (31.3)911 (100) 5 MID Study

32 Outcome: Normal Function vs different grades of DD Grade of Diastolic Dysfunction Hazard Ratio (95% CI)p value Grade 1 / Mild1.177 (0.859 – 1.612)0.309 Grade 2 / Moderate1.363 (1.001 – 1.857)0.049 Grade 3 / Severe2.416 (1.075 – 5.434)0.033

33 5 MID Study Outcome: Normal Function vs different grades of DD Grade of Diastolic Dysfunction Hazard Ratio (95% CI)p value Grade 1 / Mild1.177 (0.859 – 1.612)0.309 Grade 2 / Moderate1.363 (1.001 – 1.857)0.049 Grade 3 / Severe2.416 (1.075 – 5.434)0.033

34 Conclusions Moderate and severe Left Ventricular DD with preserved ejection fraction was associated with worsened 5-year all-cause mortality. Mortality was worse when DD was more severe. Mild DD had no significant impact on survival. 5 MID Study

35 Strengths and Limitations Strengths: Long follow up One of the very few mortality studies based on grades of Left Ventricular Diastolic Dysfunction Good number of subjects in the cohort Limitations: Retrospective nature Single Geographical Location Unequal representation of both genders 5 MID Study

36 Future Considerations Can Diastolic Dysfunction be defined a significant precursor for development of DHF? As Impaired Fasting Glucose or Impaired Glucose Tolerance is for Diabetes Mellitus As Prehypertension is for Hypertension Can aggressive control of DD risk factors prevent progression to DHF? 5 MID Study

37 References Burden of systolic and diastolic ventricular dysfunction in the community: appreciating the scope of the heart failure epidemic; Redfield MM et al; JAMA. 2003;289(2):194. Mortality rate in patients with diastolic dysfunction and normal systolic function; Halley CM et al; Arch Intern Med. 2011;171(12):1082. Owan TE, Hodge DO, Herges RM, Jacobsen SJ, Roger VL, Redfield MM. Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med. 2006;355:251-9. [PMID: 16855265] Lam CS, Donal E, Kraigher-Krainer E, Vasan RS. Epidemiology and clinical course of heart failure with preserved ejection fraction. Eur J Heart Fail. 2011;13:18-28. [PMID: 20685685] Mitral ratio of peak early to late diastolic filling velocity as a predictor of mortality in middle-aged and elderly adults: the Strong Heart Study; Bella JN et al; Circulation. 2002;105(16):1928 www.biodigital.com http://www.learntheheart.com/GADD-echoClassification.html 5 MID Study

38 Acknowledgements Continuous support and mentoring Dr. Khalid QaziDr. Khalid Qazi Dr. Henri WoodmanDr. Henri Woodman Dr. Azhar SupariwalaDr. Azhar Supariwala Institutional Review Board Dr. Sateesh SatchidanandDr. Sateesh Satchidanand Danielle CasucciDanielle Casucci Catholic Health System – IRBCatholic Health System – IRB Echo Lab Staff at Sisters of Charity Hospital 5 MID Study

39 Methods

Download ppt "5 MID Study 5 Year Mortality in Patients with Left Ventricular Diastolic Dysfunction and Preserved Ejection Fraction Catholic Health System, Buffalo, NY."

Similar presentations

Dementia IGHC Tatiana Kuznetsova, Jan A. Staessen University of Leuven, Belgium Diagnostic criteria for subclinical systolic and diastolic LV function.

Dementia IGHC Tatiana Kuznetsova, Jan A. Staessen University of Leuven, Belgium Diagnostic criteria for subclinical systolic and diastolic LV function.
Perioperative Management of Heart Failure Gamal Fouad S Zaki, MD Professor of Anesthesiology Ain Shams University

Perioperative Management of Heart Failure Gamal Fouad S Zaki, MD Professor of Anesthesiology Ain Shams University
Diastolic Heart Failure, HFpEF, HFnEF: What are we treating anyway? Charles M. Rasmussen, MD FACC.

Diastolic Heart Failure, HFpEF, HFnEF: What are we treating anyway? Charles M. Rasmussen, MD FACC.
Kelley M. Anderson, PhD, FNP

Kelley M. Anderson, PhD, FNP
Effects of selective heart rate reduction with ivabradine on left ventricular remodelling and function: results from the SHIFT echocardiography substudy.

Effects of selective heart rate reduction with ivabradine on left ventricular remodelling and function: results from the SHIFT echocardiography substudy.
Comparison of the New Mayo Clinic Risk Scores and Clinical SYNTAX Score in Predicting Adverse Cardiovascular Outcomes following Percutaneous Coronary Intervention.

Comparison of the New Mayo Clinic Risk Scores and Clinical SYNTAX Score in Predicting Adverse Cardiovascular Outcomes following Percutaneous Coronary Intervention.
Manoel Otávio da Costa Rocha UNIVERSIDADE FEDERAL DE MINAS GERAIS - FACULDADE DE MEDICINA PROGRAMA DE PÓS-GRADUAÇÃO EM CIÊNCIAS DA SAÚDE: INFECTOLOGIA.

Manoel Otávio da Costa Rocha UNIVERSIDADE FEDERAL DE MINAS GERAIS - FACULDADE DE MEDICINA PROGRAMA DE PÓS-GRADUAÇÃO EM CIÊNCIAS DA SAÚDE: INFECTOLOGIA.
© Continuing Medical Implementation …...bridging the care gap Valvular Heart Disease Aortic Stenosis.

© Continuing Medical Implementation …...bridging the care gap Valvular Heart Disease Aortic Stenosis.
Heart Failure with Normal Systolic Function: Better or Worse Prognosis? Maria Rosa Costanzo, M.D., F.A.C.C, F.A.H.A. Medical Director, Midwest Heart Specialists.

Heart Failure with Normal Systolic Function: Better or Worse Prognosis? Maria Rosa Costanzo, M.D., F.A.C.C, F.A.H.A. Medical Director, Midwest Heart Specialists.
Diabetes Mellitus As a Risk Factor for Right Ventricular Dysfunction and Impact on Mortality by Zubair Shah, PGY-III Research Mentor: Dr. Yuji Saito, M.D.,

Diabetes Mellitus As a Risk Factor for Right Ventricular Dysfunction and Impact on Mortality by Zubair Shah, PGY-III Research Mentor: Dr. Yuji Saito, M.D.,
Assessment of Diastolic function by echo

Assessment of Diastolic function by echo
Asymptomatic Aortic Stenosis and Exercise Test

Asymptomatic Aortic Stenosis and Exercise Test
Diastolic Dysfunction Dr. S. Parthasarathy MD., DA., DNB, MD (Acu), Dip. Diab.DCA, Dip. Software statistics PhD (physio)

Diastolic Dysfunction Dr. S. Parthasarathy MD., DA., DNB, MD (Acu), Dip. Diab.DCA, Dip. Software statistics PhD (physio)
Investigator Investigator: Sharma Kattel, MBBS Mentor: Mentor: Yuji Saito, MD, PhD, FACP, FACC Department of Internal Medicine Sisters of Charity Hospital.

Investigator Investigator: Sharma Kattel, MBBS Mentor: Mentor: Yuji Saito, MD, PhD, FACP, FACC Department of Internal Medicine Sisters of Charity Hospital.
Diastolic Dysfunction as Diagnosed and Quantified by Echocardiography LAM-1965AO (07/13) For Broker/Dealer Use Only.

Diastolic Dysfunction as Diagnosed and Quantified by Echocardiography LAM-1965AO (07/13) For Broker/Dealer Use Only.
Ventricular Diastolic Filling and Function

Ventricular Diastolic Filling and Function
Jennifer Doria-del Castillo

Jennifer Doria-del Castillo
CHARM-Preserved: Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity - Preserved Purpose To determine whether the angiotensin.

CHARM-Preserved: Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity - Preserved Purpose To determine whether the angiotensin.
Effect of ivabradine on recurrent hospitalization for worsening heart failure: findings from SHIFT S ystolic H eart failure treatment with the I f inhibitor.

Effect of ivabradine on recurrent hospitalization for worsening heart failure: findings from SHIFT S ystolic H eart failure treatment with the I f inhibitor.
Muhammad S Ajmal MBBS Aravind Herle MD FACC. Atrial fibrillation (AF) A supraventricular tachyarrhythmia characterized by uncoordinated atrial activation.

Muhammad S Ajmal MBBS Aravind Herle MD FACC. Atrial fibrillation (AF) A supraventricular tachyarrhythmia characterized by uncoordinated atrial activation.

Similar presentations

Ads by Google